BPI Labs, LLC

BPI Labs, LLC is an FDA-registered drug manufacturer and 503B outsourcing facility, operating as a wholly owned subsidiary of Belcher Pharmaceuticals, LLC. Founded in 2012, the company is headquartered in Largo, Florida. Employee counts vary across sources, with estimates ranging from 51-200, 201-500, to 88 employees. Similarly, estimated annual revenue ranges from under $5 million to between $50 million and $100 million.

The company specializes in the development, production, and distribution of high-quality sterile injectable pharmaceuticals and compounded medications, serving hospitals, clinics, and healthcare providers across the United States. BPI Labs utilizes advanced, humanless robotic manufacturing technology within ISO-grade isolated suites to ensure compliance with current Good Manufacturing Practices (cGMP). Their mission includes addressing nationwide drug shortages and unmet clinical needs.

BPI Labs, LLC exhibits an active patent litigation posture as an operating company. While the provided case data indicates one plaintiff case, BPI Labs, LLC v. Eli Lilly & Co. at the Patent Trial and Appeal Board (PTAB) in 2025, external records show the company has also been a defendant in Abbreviated New Drug Application (ANDA) patent litigation. Specifically, they were defendants in cases brought by Endo Par Innovation Co. and American Regent, Inc. This indicates BPI Labs, LLC both asserts its own patent interests and defends against infringement claims related to its pharmaceutical products.

A notable case is BPI Labs, LLC v. Eli Lilly & Co. (IPR2025-01346), filed on August 4, 2025, at the PTAB. In this inter partes review, BPI Labs, LLC collaborated with Empower Pharmacy to challenge the validity of Eli Lilly's U.S. Patent No. 9,474,780, which covers tirzepatide (marketed as Mounjaro and Zepbound). They argue that Lilly's claims were obvious based on prior art. This challenge reflects a broader effort by compounding pharmacies to contest the exclusivity of major pharmaceutical patents, driven by patient advocacy and demand for more affordable treatment options.